Comparative Pharmacology
Head-to-head clinical analysis: INVELTYS versus PREDAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVELTYS versus PREDAMIDE.
INVELTYS vs PREDAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid; modulates inflammatory response by binding to glucocorticoid receptors, altering gene expression and suppressing pro-inflammatory cytokines.
Predamide (a combination of prednisolone and sulfadimethoxine) exerts its effects via the corticosteroid anti-inflammatory action of prednisolone (inhibition of phospholipase A2, reduced prostaglandin synthesis) and the bacteriostatic action of sulfadimethoxine (competitive antagonism of para-aminobenzoic acid, inhibiting dihydropteroate synthase in folate synthesis).
Instill 1 drop into the affected eye(s) four times daily for 14 days, then taper as clinically indicated.
Prednisone 5 mg orally once daily, adjusted based on response.
None Documented
None Documented
Approximately 1.5 hours (range 1-2 hours) for the ophthalmic suspension; terminal half-life in systemic circulation is about 3 hours after topical ocular administration.
Terminal elimination half-life: 12-15 hours. In hepatic impairment, half-life may extend to 20-25 hours; in renal impairment (CrCl <30 mL/min), half-life increases to 30-40 hours.
Primarily hepatic metabolism with minimal renal excretion (<5% unchanged in urine). Fecal elimination accounts for approximately 20% of the dose.
Renal (80% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates), biliary/fecal (20%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination